Sinovac Begins Phase 3 COVID-19 Vaccine Trial in Indonesia

Chinese drugmaker Sinovac has begun a phase 3 trial of its COVID-19 vaccine CoronaVac in Indonesia in partnership with state-owned Indonesian drugmaker Bio Farma.

CoronaVac uses an inactivated form of the coronavirus to prompt  an immune response. In a phase 2 trial, it induced neutralizing antibodies in 90 percent of participants.

The only local vaccine manufacturer in Indonesia, Bio Farma expects to begin commercial production in six months. CoronaVac is also in phase 3 testing in Brazil.